Dyne Therapeutics, Inc. DYN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
46/100
Developing

Ranked against 712 peers in Biotechnology

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE … Full DYN analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.95), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.38), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where DYN ranks in Biotechnology

Dyne Therapeutics, Inc. ranks #282 of 713 scored companies in Biotechnology by moat score — the top 40%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
278 Northwest Biotherapeutics, Inc. NWBO 47/100 Developing
279 Gossamer Bio, Inc. GOSS 46/100 Developing
280 Aldeyra Therapeutics, Inc. ALDX 46/100 Developing
281 Centessa Pharmaceuticals plc CNTA 46/100 Developing
282 Dyne Therapeutics, Inc. DYN 46/100 Developing
283 CASI Pharmaceuticals, Inc. CASI 46/100 Developing
284 Cogent Biosciences, Inc. COGT 46/100 Developing
285 Opus Genetics, Inc. IRD 46/100 Developing
286 AN2 Therapeutics, Inc. ANTX 46/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How DYN scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 60 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding DYN's moat

What is Dyne Therapeutics, Inc.'s moat score?

Dyne Therapeutics, Inc. (DYN) scores 46 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #282 of 713 scored companies in Biotechnology, the top 40%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (60/100) and its weakest is Capital Efficiency (38/100).

How does Dyne Therapeutics, Inc. compare with other Biotechnology companies?

Dyne Therapeutics, Inc. ranks #282 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Centessa Pharmaceuticals plc (CNTA) at 46 just above it and CASI Pharmaceuticals, Inc. (CASI) at 46 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Dyne Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Dyne Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and DYN scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (38), Resilience (60), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000